Pfizer, Inc. (PFE) had an volatile session and gained 0.26 points till last call. The price was at $31.67, gaining 0.83% till the last intraday data. The total uptick value was $107.5 million while the total downtick value was $127.14 million. The shares saw a net money flow of $(-19.64) million and the up/down ratio stood at 0.85. The stock has seen a change of of 0.8% for the week. The share had a block transaction during the course of trading in which the net money flow was $(-16.58) million. Almost $8.91 million were received in upticks and approximately $25.49 million were lost in downticks, thereby giving the up/down ratio of 0.35.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of Pfizer Inc. appreciated by 1.21% during the last five trading days but lost 2.49% on a 4-week basis. Pfizer Inc. is up 0.87% in the last 3-month period. Year-to-Date the stock performance stands at -2.49%. Pfizer, Inc. (NYSE:PFE) rose 0.83% or 0.26 points on Wednesday and made its way into the gainers of the day. After trading began at $31.51 the stock was seen hitting $31.69 as a peak level and $31.26 as the lowest level. The stock ended up at $31.67. The daily volume was measured at 28,493,260 shares. The 52-week high of the share price is $37.39 and the 52-week low is $28.25. The company has a market cap of $192,185 million.
Company has reported several Insider transactions to the SEC, on Nov 10, 2016, Anthony J Maddaluna (Executive Vice President) sold 10,000 shares at 33.00 per share price.On Nov 7, 2016, Albert Bourla (Group President) sold 18,390 shares at 30.05 per share price.On May 27, 2016, Frank A Damelio (Executive Vice President) sold 100,000 shares at 34.49 per share price.
Pfizer Last issued its quarterly earnings results on Jan 31, 2017. The company reported $0.47 EPS for the quarter, missing the analyst consensus estimate by $ -0.04. Analyst had a consensus of $0.51. The company had revenue of $13627.00 million for the quarter, compared to analysts expectations of $13689.67 million. The companys revenue was down -3.0 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.53 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Pfizer was Initiated by Guggenheim to Neutral on Dec 2, 2016.
Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Companys diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Pfizers Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. is headquartered in New York.